COVID-19 data scandal prompts tweaks to elite journal’s review process | Science | AAAS

COVID-19 data scandal prompts tweaks to elite journal’s review process | Science | AAAS

Lancet reacts to big COVID retraction

The Lancet has announced policies that it hopes will prevent a repeat of a high-profile retraction of a COVID-19 study that relied on a proprietary commercial data set. The journal will now require, among other things, that more than one author on a paper has seen and verified its underlying data. For academic–commercial collaborations, one of those authors must be from academia. And one of the peer-reviewers must have detailed knowledge of the data in question.

Science | 5 min read
Read more: High-profile coronavirus retractions raise concerns about data oversight (Nature | 7 min read, from June)Reference: The Lancet comment article